|
|
 |
|
Viewing report
|
|
|
|
Antibacterials: Market Forecast
Datamonitor, Feb 2011
Introduction
Over the next decade, the fragmented antibacterials market will shift away from a blockbuster-business model, as generic erosion of market leaders and increased competition between new hospital drugs will trigger a decline in sales of branded antibacterials. While there is a lack of innovation with regards to new community drugs, the hospital sector will remain the only notable source of growth.
Features and benefits
- Detailed ten-year sales forecasts for marketed antibacterial drugs in each of the seven major markets
- Analysis of the antibacterials market across the US, Japan, France, Italy, Germany, Spain and the UK
Highlights
- Over the next decade, genericization of key brands will drive a significant decline in market value, contributing to a loss of revenues of $3.2bn from Levaquin/Cravit/Tavanic, Zosyn/Tazocin, and Zyvox alone by 2019. Combined with growing resistance, this will cause increasing market fragmentation and reduce the potential for “blockbuster” sales.
- The late-stage pipeline, much of which is targeting MRSA, will generate revenues totaling nearly $2.0bn by 2019. However, Datamonitor predicts that this upside will be insufficient to offset the decline caused by genericization, and total seven major market sales will fall from $19.6bn in 2009 to $16.4bn in 2019, with a CAGR of -1.8%.
Your key questions answered
- Assess and quantify the market opportunity for antibacterials, from generics to high-priced hospital brands.
- Assess the impact of key issues affecting the antibacterials market; generic erosion and growing levels of resistance
|
|
|
|
